Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.

Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr, Choy H.

J Clin Oncol. 2019 Dec 16:JCO1901162. doi: 10.1200/JCO.19.01162. [Epub ahead of print]

PMID:
31841363
2.

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.

Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM.

J Thorac Oncol. 2019 Nov;14(11):1901-1911. doi: 10.1016/j.jtho.2019.08.003. Epub 2019 Aug 22.

PMID:
31446141
3.

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV.

J Clin Oncol. 2019 Jun 20;37(18):1558-1565. doi: 10.1200/JCO.19.00201. Epub 2019 May 8.

PMID:
31067138
4.

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.

Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR Jr, Lee JJ, Heymach JV, Zhang J.

J Thorac Oncol. 2019 Jun;14(6):1021-1031. doi: 10.1016/j.jtho.2019.02.008. Epub 2019 Feb 16.

PMID:
30780001
5.

Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.

Wheatley-Price P, Gadgeel S, Takahashi T, Li X, Dar M, Blumenschein GR Jr.

Clin Lung Cancer. 2019 May;20(3):e362-e368. doi: 10.1016/j.cllc.2018.11.012. Epub 2018 Nov 29.

PMID:
30685114
6.

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.

Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549.

PMID:
30596812
7.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

8.

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR Jr, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R.

J Clin Oncol. 2018 Jun 20;36(18):1813-1822. doi: 10.1200/JCO.2017.74.0720. Epub 2018 Jan 2. Erratum in: J Clin Oncol. 2018 Aug 20;36(24):2570.

9.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

10.

Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.

Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X.

J Clin Oncol. 2017 Sep 1;35(25):2885-2892. doi: 10.1200/JCO.2016.71.4758. Epub 2017 May 11.

11.

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV.

Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.

12.

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.

Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA.

Oncotarget. 2016 Apr 26;7(17):23227-38. doi: 10.18632/oncotarget.7594.

13.

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR.

N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.

14.

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.

Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR Jr, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J.

Clin Cancer Res. 2015 Jun 1;21(11):2462-70. doi: 10.1158/1078-0432.CCR-14-2412.

15.

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V.

Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29.

16.

Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival.

Gomez DR, Liao KP, Swisher SG, Blumenschein GR, Erasmus JJ Jr, Buchholz TA, Giordano SH, Smith BD.

Radiother Oncol. 2015 May;115(2):257-63. doi: 10.1016/j.radonc.2015.04.010. Epub 2015 May 23.

PMID:
26013292
17.

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.

Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):317-24. doi: 10.1016/j.ijrobp.2015.02.005.

18.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA.

Ann Oncol. 2015 May;26(5):894-901. doi: 10.1093/annonc/mdv072. Epub 2015 Feb 26.

19.

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.

Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR Jr, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM.

Oncotarget. 2014 Oct 15;5(19):8937-46.

20.

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM.

Oncologist. 2014 Oct;19(10):1040-1. doi: 10.1634/theoncologist.2014-0228. Epub 2014 Aug 28.

21.

EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.

Komaki R, Paulus R, Blumenschein GR Jr, Curran WJ Jr, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK.

Radiother Oncol. 2014 Jul;112(1):30-6. doi: 10.1016/j.radonc.2014.06.012. Epub 2014 Jul 16.

22.

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.

Ganesan P, Ali SM, Wang K, Blumenschein GR, Esmaeli B, Wolff RA, Miller VA, Stephens PJ, Ross JS, Palmer GA, Janku F.

J Clin Oncol. 2016 Feb 10;34(5):e34-7. doi: 10.1200/JCO.2013.50.3516. Epub 2014 Jun 16. No abstract available.

PMID:
24934779
23.

Phase II study of gefitinib in patients with advanced salivary gland cancers.

Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR Jr.

Head Neck. 2015 May;37(5):644-9. doi: 10.1002/hed.23647. Epub 2015 Mar 30.

24.

Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.

Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM.

Clin Cancer Res. 2013 Dec 15;19(24):6967-75. doi: 10.1158/1078-0432.CCR-12-1818. Epub 2013 Oct 28.

25.

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC.

J Clin Oncol. 2013 Nov 10;31(32):4105-14. doi: 10.1200/JCO.2012.47.4189. Epub 2013 Oct 7.

26.

Mesothelin expression and survival outcomes in triple receptor negative breast cancer.

Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM.

Clin Breast Cancer. 2013 Oct;13(5):378-84. doi: 10.1016/j.clbc.2013.05.001. Epub 2013 Jun 27.

27.

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR Jr.

Ann Oncol. 2013 Sep;24(9):2382-9. doi: 10.1093/annonc/mdt212. Epub 2013 Jun 20.

28.

[Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].

Shepherd FA, Douillard JY, Blumenschein GR.

Zhongguo Fei Ai Za Zhi. 2013 Apr;16(4):C9-20. doi: 10.3779/j.issn.1009-3419.2013.04.09. Review. Chinese.

29.

Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.

Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR Jr, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK.

J Thorac Oncol. 2013 May;8(5):658-61. doi: 10.1097/JTO.0b013e31828d08ae.

30.

Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.

Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S.

J Thorac Oncol. 2013 Apr;8(4):436-42. doi: 10.1097/JTO.0b013e318287c91e.

31.

Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.

Gonzalez-Angulo AM, Blumenschein GR Jr.

Cancer Treat Rev. 2013 Jun;39(4):313-20. doi: 10.1016/j.ctrv.2012.11.002. Epub 2012 Dec 6.

32.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

33.

Role of HGF/MET axis in resistance of lung cancer to contemporary management.

Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr.

Transl Lung Cancer Res. 2012 Sep;1(3):179-93. doi: 10.3978/j.issn.2218-6751.2012.09.04. Review.

34.

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S.

Ann Oncol. 2013 Jan;24(1):220-5. doi: 10.1093/annonc/mds245. Epub 2012 Aug 16.

35.

Targeting the hepatocyte growth factor-cMET axis in cancer therapy.

Blumenschein GR Jr, Mills GB, Gonzalez-Angulo AM.

J Clin Oncol. 2012 Sep 10;30(26):3287-96. doi: 10.1200/JCO.2011.40.3774. Epub 2012 Aug 6.

36.

Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.

Blumenschein GR Jr, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E.

J Thorac Oncol. 2012 Sep;7(9):1406-16.

37.

Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.

Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR Jr.

Cancer. 2013 Jan 1;119(1):7-15. doi: 10.1002/cncr.27608. Epub 2012 Jun 26.

38.

The BATTLE trial: personalizing therapy for lung cancer.

Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK.

Cancer Discov. 2011 Jun;1(1):44-53. doi: 10.1158/2159-8274.CD-10-0010. Epub 2011 Jun 1.

39.

cMET and phospho-cMET protein levels in breast cancers and survival outcomes.

Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR Jr, Gonzalez-Angulo AM.

Clin Cancer Res. 2012 Apr 15;18(8):2269-77. doi: 10.1158/1078-0432.CCR-11-2830. Epub 2012 Feb 28.

40.

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G.

J Natl Cancer Inst. 2012 Feb 8;104(3):228-39. doi: 10.1093/jnci/djr523. Epub 2012 Jan 13.

41.

Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC).

Blumenschein GR Jr.

Invest New Drugs. 2012 Aug;30(4):1802-11. doi: 10.1007/s10637-011-9750-1. Epub 2011 Oct 11. Review.

PMID:
21987350
42.

Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.

Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ.

J Thorac Oncol. 2011 Dec;6(12):2104-11. doi: 10.1097/JTO.0b013e31822e7256.

43.

Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.

Shepherd FA, Douillard JY, Blumenschein GR Jr.

J Thorac Oncol. 2011 Oct;6(10):1763-73. doi: 10.1097/JTO.0b013e31822e28fc. Review. Erratum in: J Thorac Oncol. 2012 Jan;7(1):266.

44.

Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.

Adjei AA, Blumenschein GR Jr, Mandrekar S, Hillman S, Gatzemeier U, Heigener D.

Clin Lung Cancer. 2011 Jul;12(4):212-7. doi: 10.1016/j.cllc.2011.03.021. Epub 2011 Apr 28.

PMID:
21726819
45.

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R.

J Clin Oncol. 2011 Jun 10;29(17):2312-8. doi: 10.1200/JCO.2010.31.7875. Epub 2011 May 9.

46.

Motesanib and advanced NSCLC: experiences and expectations.

Raghav KP, Blumenschein GR.

Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. doi: 10.1517/13543784.2011.579103. Epub 2011 May 2. Review.

PMID:
21534718
47.

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.

Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L; Motesanib NSCLC Phase II Study Investigators.

Ann Oncol. 2011 Sep;22(9):2057-67. doi: 10.1093/annonc/mdq731. Epub 2011 Feb 14.

PMID:
21321086
48.

Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.

Blumenschein GR Jr, Reck M, Fossella F, Stewart DJ, Lathia C, Peña C.

Cancer Biomark. 2011-2012;10(6):287-98. doi: 10.3233/CBM-2012-0253.

PMID:
22820084
49.

Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.

Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR Jr, Kies MS.

Front Oncol. 2011 Dec 13;1:52. doi: 10.3389/fonc.2011.00052. eCollection 2011.

50.

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.

Heath EI, Blumenschein GR Jr, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G.

Cancer Chemother Pharmacol. 2011 Sep;68(3):703-12. doi: 10.1007/s00280-010-1536-1. Epub 2010 Dec 8.

Supplemental Content

Loading ...
Support Center